Potassium Carbonate → HCID 10172676, 화합물

HRID 479116

반응식

HRID 479116 반응식
OC(C(F)(F)F)=O.[N:8]1([CH2:14][C:15]2[N:16]=[N:17][C:18]3[C:19](=[C:21]([NH2:26])[N:22]=[C:23]([NH2:25])[N:24]=3)[N:20]=2)[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]1.[CH3:27][C:28]1[CH:35]=[C:34]([CH3:36])[CH:33]=[CH:32][C:29]=1[CH2:30]Cl.C(=O)([O-])[O-].[K+].[K+].CC#N.O>CN(C=O)C>[CH3:27][C:28]1[CH:35]=[C:34]([CH3:36])[CH:33]=[CH:32][C:29]=1[CH2:30][N:11]1[CH2:12][CH2:13][N:8]([CH2:14][C:15]2[N:16]=[N:17][C:18]3[C:19](=[C:21]([NH2:26])[N:22]=[C:23]([NH2:25])[N:24]=3)[N:20]=2)[CH2:9][CH2:10]1

참가 물질

6

실험 절차

To a stirred solution of 3-Piperazin-1-ylmethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-diamine TFA salt 5 (50 mg; 0.08 mmol; prepared in EXAMPLE 4) in dry DMF (1.0 mL) was added 2,4-dimethylbenzyl chloride (0.020 mL; 0.13 mmol) followed by potassium carbonate (55 mg; 0.40 mmol). The mixture was allowed to stir for 24 h at room temperature then taken up into CH3CN/H2O/0.1% TFA. The mixture was purified by reverse phase HPLC (Rainin C18, 0% CH3CN to 50% CH3CN gradient, CH3CN/H2O, 0.1% TFA) and the bright yellow fractions containing the product were lyophilized after removal of CH3CN in vacuo to give 10 mg of yellow colored 3-[4-(2,4-Dimethyl-benzyl)-piperazin-1-ylmethyl]-pyrimido[5,4-e][1,2,4]triazine-5,7-diamine as the trifluoroacetate salt. 1H NMR (dmso-d6, ppm): 9.40 (bs, 1H), 8.17 (bs, 2H), 7.00-7.40 (m, 3H), 4.28 (bs, 2H), 4.10 (bs, 2H), 2.95-3.35 (m, 8H), 2.34 (s, 3H), 2.28 (s, 3H).

후처리

  1. customThe mixture was purified by reverse phase HPLC (Rainin C18, 0% CH3CN to 50% CH3CN gradient, CH3CN/H2O, 0.1% TFA)
  2. additionthe bright yellow fractions containing the product
  3. customafter removal of CH3CN in vacuo

출처 및 근거

ORD 기록
ord-330594d3d3514521b810e1330aff4d5d
출처 데이터셋
uspto-grants-2003_11
특허 번호
US06642381B2

연결된 노트

불러오는 중…